Comparing preoperative and postoperative blood clot prevention for liver surgery
Official title: Pre- Vs Postoperative Thromboprophylaxis for Liver Resection - a Prospective, Multicenter, Randomized Controlled Trial
Run by Helsinki University Central Hospital · NCT04731558 · Data updated 2026-11-12
This study is testing whether giving blood clot prevention medicine before or after liver surgery works better to keep patients safe from clots.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1012 (estimated) |
| Sponsor | Helsinki University Central Hospital Academic / other |
| Locations | 7 sites (Helsinki and 6 other locations) |
| Status | Recruiting |
| Started | February 10, 2021 |
| Main results expected | February 2027 |
| Study ends | March 2027 |
| Registry record updated | February 14, 2025 |
| Trial ID | NCT04731558 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients scheduled for liver resection who are not on anticoagulant medications.
✕Probably not a fit
Patients who are on anticoagulant medications, require emergency surgery, or are under 18 years old may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the timing of thromboprophylaxis in patients undergoing liver resection, comparing preoperative versus postoperative administration of anticoagulants like enoxaparin, tinzaparin, or dalteparin. The study aims to address the lack of consensus and low-quality evidence surrounding thrombosis prevention in liver surgery, which is critical due to the associated risks of bleeding. By enrolling patients who meet specific criteria, the trial seeks to provide clearer guidelines on the optimal timing for thromboprophylaxis in this patient population.
Why it matters
Potential benefit: If successful, this study could lead to improved guidelines for preventing blood clots in liver surgery patients, potentially reducing complications and improving recovery.
How similar studies have gone: There is currently no known prospective randomized trial addressing this specific timing of thromboprophylaxis in liver surgery, making this approach novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients undergoing liver resection Exclusion Criteria: * Patient on anticoagulative medication (heparin, low-molecular weight heparin, warfarin, direct oral anticoagulants) during last month pre-surgery * Emergency operation (e.g. for trauma or infection) * Age \< 18 years * Allergy or other contraindication to planned low-molecular weight heparin * Inability to give written informed consent * Liver resection not performed (removed from analyses after randomization)
Where it's running
-
Helsinki University Hospital
Helsinki, Finland Recruiting -
Kuopio University Hospital
Kuopio, Finland Recruiting -
Tampere University Hospital
Tampere, Finland Recruiting -
Oslo University Hospital
Oslo, Norway Recruiting -
University Hospital of North Norway
Tromsø, Norway Recruiting -
Oulu University Hospital
Oulu, Finland Not yet recruiting
Show 1 more location
-
Turku University Hospital
Turku, Finland Not yet recruiting
Study contacts
- Study coordinator: Ville Sallinen, MD, PhD
- Email: ville.sallinen@helsinki.fi
- Phone: +358-9-4711
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Safety of perioperative blood thinner management in people with cancer undergoing surgery or procedures
This study tests how safe current practices are for stopping or continuing blood thinners in adults with cancer who are having surgery or procedures, to see if bleeding or clots are affected.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer
This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.
-
Protoacoustic Imaging to See Radiation Delivery in Proton Therapy
This study tests radioacoustic imaging with ultrasound to help doctors see where proton therapy is delivering radiation for liver and prostate cancer patients.
-
Antiplatelet-Only versus Antiplatelet plus Low-Dose Rivaroxaban after Heart Events
In adults 65 or older with prior heart events and certain arterial diseases, this study tests whether continuing clopidogrel alone is no worse than adding low-dose rivaroxaban to aspirin-based therapy.
-
YMN-136 vaccine for advanced liver, biliary tract, and pancreatic cancers
A first-in-human dose-escalation study tests whether the YMN-136 vaccine is safe and tolerable for adults with unresectable advanced liver, biliary tract, or pancreatic cancers who have progressed on standard therapies or cannot receive them.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.